Investegate |Vectura Group plc Announcements | Vectura Group plc: Prelim Results revised date, guidance unchanged
Investegate announcements from Vectura Group plc, Prelim Results revised date, guidance unchanged
Stay updated with breaking news from David Ginivan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Vectura Group plc, Prelim Results revised date, guidance unchanged
Investegate announcements from Vectura Group plc, Notice of Results
Chippenham, UK - 30 December 2020: Vectura Group plc (LSE: VEC) ("Vectura", the "Group", or the "Company"), an industry-leading specialist inhalation CDMO, is pleased to announce the appointments of Jeanne Hecht and Jeanne Thoma as Independent Non-Executive Directors of the Company with effect from 31 st December 2020. Jeanne Hecht was most recently CEO of Ora, Inc. ("Ora") a full-service pre-clinical and clinical ophthalmic drug and device development firm. Previously she served as Chief Operating Officer and was a Board Director of Median Technologies, a clinical services...
Vectura Group plc Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565 Mary-Jane Elliott / Sue Stuart / David Daley About Vectura Vectura is a provider of innovative inhaled drug delivery solutions that enable partners and customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapie...